Literature DB >> 26986923

The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer.

Aaron Lisberg1, Edward B Garon1.   

Abstract

Entities:  

Year:  2016        PMID： 26986923     DOI： 10.1001/jamaoncol.2016.0043

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.

Authors:  Ross A Soo; Joey Sze Yun Lim; Bernadette Reyna Asuncion; Zul Fazreen; Maria Cynthia Herrera; Mohd Feroz Mohd Omar; Nguyen Hoang Diem Phuong; Ju Ee Seet; Benhur Amanuel; Barry Iacopetta; David Byrne; Shona Hendry; Stephen Fox; Richie Soong
Journal:  Oncotarget       Date:  2018-01-02

2.  PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.

Authors:  Cuiling Zhou; Jianjun Tang; Huanhuan Sun; Xiaobin Zheng; Zhanyu Li; Tiantian Sun; Jie Li; Shuncong Wang; Xiuling Zhou; Hongliu Sun; Zhibin Cheng; Hongyu Zhang; Haiqing Ma
Journal:  Oncotarget       Date:  2017-04-11

3.  Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.

Authors:  Sonja Althammer; Tze Heng Tan; Andreas Spitzmüller; Lorenz Rognoni; Tobias Wiestler; Thomas Herz; Moritz Widmaier; Marlon C Rebelatto; Helene Kaplon; Diane Damotte; Marco Alifano; Scott A Hammond; Marie-Caroline Dieu-Nosjean; Koustubh Ranade; Guenter Schmidt; Brandon W Higgs; Keith E Steele
Journal:  J Immunother Cancer       Date:  2019-05-06       Impact factor: 13.751

4.  Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.

Authors:  Manjima Dhar; Jessica Wong; James Che; Melissa Matsumoto; Tristan Grogan; David Elashoff; Edward B Garon; Jonathan W Goldman; Elodie Sollier Christen; Dino Di Carlo; Rajan P Kulkarni
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

5.  Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.

Authors:  Selene Ottonello; Carlo Genova; Irene Cossu; Vincenzo Fontana; Erika Rijavec; Giovanni Rossi; Federica Biello; Maria Giovanna Dal Bello; Marco Tagliamento; Angela Alama; Simona Coco; Simona Boccardo; Irene Vanni; Guido Ferlazzo; Lorenzo Moretta; Francesco Grossi; Maria Cristina Mingari; Paolo Carrega; Gabriella Pietra
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

Review 6.  BRAF inhibitors: resistance and the promise of combination treatments for melanoma.

Authors:  Merope Griffin; Daniele Scotto; Debra H Josephs; Silvia Mele; Silvia Crescioli; Heather J Bax; Giulia Pellizzari; Matthew D Wynne; Mano Nakamura; Ricarda M Hoffmann; Kristina M Ilieva; Anthony Cheung; James F Spicer; Sophie Papa; Katie E Lacy; Sophia N Karagiannis
Journal:  Oncotarget       Date:  2017-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.